title: The Judgment of Paris: treatment dilemmas in advanced renal cell carcinoma.
authors: Henry Ford Health Systems, Detroit, MI.
authors: Clara
authors: C
authors: Hwang
authors: Elisabeth I
authors: EI
authors: Heath
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D001706:Biopsy; D002292:Carcinoma, Renal Cell / Q000098:blood supply / Q000201:enzymology / Q000556:secondary / Q000628:therapy*; D018450:Disease Progression; D017809:Fatal Outcome; D006801:Humans; D007680:Kidney Neoplasms / Q000098:blood supply / Q000201:enzymology / Q000473:pathology / Q000628:therapy*; D008113:Liver Neoplasms / Q000556:secondary; D008175:Lung Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000201:enzymology / Q000556:secondary; D008297:Male; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D009392:Nephrectomy; D018579:Patient Selection; D057285:Precision Medicine; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000378:metabolism; D058570:TOR Serine-Threonine Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism; D013997:Time Factors; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D020533:Angiogenesis Inhibitors; D047428:Protein Kinase Inhibitors; C546842:MTOR protein, human; D040262:Receptors, Vascular Endothelial Growth Factor; D058570:TOR Serine-Threonine Kinases